53 related articles for article (PubMed ID: 20127952)
1. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer.
Kraeber-Bodéré F; Salaun PY; Oudoux A; Goldenberg DM; Chatal JF; Barbet J
Cancer; 2010 Feb; 116(4 Suppl):1118-25. PubMed ID: 20127952
[TBL] [Abstract][Full Text] [Related]
2. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
Chatal JF; Campion L; Kraeber-Bodéré F; Bardet S; Vuillez JP; Charbonnel B; Rohmer V; Chang CH; Sharkey RM; Goldenberg DM; Barbet J;
J Clin Oncol; 2006 Apr; 24(11):1705-11. PubMed ID: 16549819
[TBL] [Abstract][Full Text] [Related]
3. Long-term prognosis of medullary thyroid carcinoma.
Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
[TBL] [Abstract][Full Text] [Related]
4. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?
Castellani MR; Seregni E; Maccauro M; Chiesa C; Aliberti G; Orunesu E; Bombardieri E
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):430-40. PubMed ID: 19088696
[TBL] [Abstract][Full Text] [Related]
5. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
6. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Salaun PY; Campion L; Bournaud C; Faivre-Chauvet A; Vuillez JP; Taieb D; Ansquer C; Rousseau C; Borson-Chazot F; Bardet S; Oudoux A; Cariou B; Mirallié E; Chang CH; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
J Nucl Med; 2012 Aug; 53(8):1185-92. PubMed ID: 22743249
[TBL] [Abstract][Full Text] [Related]
9. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.
Pelizzo MR; Boschin IM; Bernante P; Toniato A; Piotto A; Pagetta C; Nibale O; Rampin L; Muzzio PC; Rubello D
Eur J Surg Oncol; 2007 May; 33(4):493-7. PubMed ID: 17125960
[TBL] [Abstract][Full Text] [Related]
10. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid cancer: early detection and novel treatments.
Roman S; Mehta P; Sosa JA
Curr Opin Oncol; 2009 Jan; 21(1):5-10. PubMed ID: 19125012
[TBL] [Abstract][Full Text] [Related]
12. Medullary thyroid carcinoma and biomarkers: past, present and future.
van Veelen W; de Groot JW; Acton DS; Hofstra RM; Höppener JW; Links TP; Lips CJ
J Intern Med; 2009 Jul; 266(1):126-40. PubMed ID: 19522831
[TBL] [Abstract][Full Text] [Related]
13. Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era.
Schwartz DL; Rana V; Shaw S; Yazbeck C; Ang KK; Morrison WH; Rosenthal DI; Hoff A; Evans DB; Clayman GL; Garden AS; Sherman SI
Head Neck; 2008 Jul; 30(7):883-8. PubMed ID: 18213725
[TBL] [Abstract][Full Text] [Related]
14. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
15. Determinants of life expectancy in medullary thyroid cancer: age does not matter.
de Groot JW; Plukker JT; Wolffenbuttel BH; Wiggers T; Sluiter WJ; Links TP
Clin Endocrinol (Oxf); 2006 Dec; 65(6):729-36. PubMed ID: 17121523
[TBL] [Abstract][Full Text] [Related]
16. ¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.
Salaun PY; Campion L; Ansquer C; Frampas E; Mathieu C; Robin P; Bournaud C; Vuillez JP; Taieb D; Rousseau C; Drui D; Mirallié E; Borson-Chazot F; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1501-10. PubMed ID: 24806110
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis.
Meijer JA; le Cessie S; van den Hout WB; Kievit J; Schoones JW; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2010 Apr; 72(4):534-42. PubMed ID: 19563448
[TBL] [Abstract][Full Text] [Related]
19. Micromedullary thyroid cancer: how micro is truly micro?
Pillarisetty VG; Katz SC; Ghossein RA; Tuttle RM; Shaha AR
Ann Surg Oncol; 2009 Oct; 16(10):2875-81. PubMed ID: 19568813
[TBL] [Abstract][Full Text] [Related]
20. Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC).
Kraeber-Bodéré F; Salaun PY; Ansquer C; Drui D; Mirallié E; Faivre-Chauvet A; Barbet J; Goldenberg DM; Chatal JF
Tumour Biol; 2012 Jun; 33(3):601-6. PubMed ID: 22396039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
